Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

NHS changes 'will delay cancer checks': Sufferers from genetic diseases 'may be denied new treatments'

Tom Wilkie,Science Editor
Tuesday 19 April 1994 23:02 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

WOMEN at risk of inherited breast cancer will not receive proper screening 'for years' even though researchers expect to identify the relevant gene within months, one of the country's foremost clinical geneticists warned yesterday.

The problem is the Government's changes to the National Health Service, as a result of which many people suffering from genetic diseases may be denied powerful new treatments, according to Professor Malcolm Ferguson-Smith of Cambridge University.

Despite repeated attempts by civil servants to cut him short, Professor Ferguson-Smith told a press conference yesterday of his 'fear that preventive medicine will lose out' in the new NHS. He warned that the 14 regional genetics centres in England and Wales could close. It would be more difficult to provide genetics services under the new system whereby individual hospitals fulfil contracts to be 'providers' of medical services which GPs and other 'purchasers' buy.

Professor Ferguson-Smith said: 'We are now thinking of breast cancer screening. We do not have the infrastructure in the present system to handle that and I can't see funds coming from the purchaser-providers to make it happen.' Once the gene is discovered, he expects that women in families with a history of the disease would come forward for testing but under the new system, he warned, 'to get the grants to do it will take years. Yet these are anxious women who need counselling and advice'.

Research into genetic disease could also be adversely affected by the changes. The existing NHS system had allowed the development of a unique set of records of patients with genetic disorders, which was proving invaluable to researchers hunting the genes responsible for human disease.

Professor Ferguson-Smith's comments echo the fears of support groups for families affected by genetic diseases. The support groups have been worried for some time that elementary treatment - such as genetic counselling - might be threatened by the internal market reforms of the NHS.

Professor Kay Davies, who heads the Medical Research Council's Clinical Sciences Centre, also told yesterday's press conference that the collection of clinical data for genetics studies was 'extremely well organised and needs to be protected against changes in the NHS'. However, Professor Davies was more hopeful: she pointed out that the Department of Health has set up an internal study group to examine the problem.

A Department of Health spokesman dismissed the fears. He said: 'This is ridiculous. The reorganisation of the regional health authorities will have no effect on funding of this kind. Applications will be considered on their merits as they always have been.'

Last November, the Department of Health set up a research task force under Professor Anthony Culyer of York University to review ways in which the NHS funds its research and development. The task force is is expected to report to ministers by the end of the month.

Geneticists expect to see huge numbers of disease-related genes being discovered as a result of an international research programme, known as the Human Genome Project. Britain is one of the leaders in this research which will map out and analyse every one of humanity's 50,000 to 100,000 genes.

Professor Davies headed a group of independent geneticists which yesterday launched a report on how British prowess in gene research can be maintained and developed.

The Human Genome Mapping Project in the UK; HMSO; pounds 9.95.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in